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Abstract: Fewer than 45% of women go through life with a full head of hair. Female pattern 
hair loss is the commonest cause of hair loss in women and prevalence increases with advancing 
age. Affected women may experience psychological distress and impaired social functioning. In 
most cases the diagnosis can be made clinically and the condition treated medically. While many 
women using oral antiandrogens and topical minoxidil will regrow some hair, early diagnosis and 
initiation of treatment is desirable as these treatments are more effective at arresting progression 
of hair loss than stimulating regrowth. Adjunctive nonpharmacological treatment modalities 
such as counseling, cosmetic camouﬂ  age and hair transplantation are important measures for 
some patients. The histology of female pattern hair loss is identical to that of male androgenetic 
alopecia. While the clinical pattern of the hair loss differs between men, the response to oral 
antiandrogens suggests that female pattern hair loss is an androgen dependant condition, at 
least in the majority of cases. Female pattern hair loss is a chronic progressive condition. All 
treatments need to be continued to maintain the effect. An initial therapeutic response often 
takes 12 or even 24 months. Given this delay, monitoring for treatment effect through clinical 
photography or standardized clinical severity scales is helpful.
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Introduction
Female pattern hair loss (FPHL) has emerged as the preferred term for androgenetic 
alopecia in females owing to the uncertain relationship between androgens and this 
entity (Olsen 2001). It is characterized by a reduction in hair density over the crown and 
frontal scalp with retention of the frontal hairline. In 1977, Ludwig clearly described 
the distinctive features of FPHL and classiﬁ  ed it into three grades of severity referred 
to as Ludwig grades I, II, and III (Figure 1; Ludwig 1977). The prevalence increases 
with age from approximately 12% amongst women aged between 20 and 29 years to 
over 50% of women over the age of 80 (Gan and Sinclair 2005). Hair loss in women 
is associated with signiﬁ  cant psychological morbidity. Cash and colleagues (1993) 
suggested that women place a greater emphasis than men on physical appearances 
and outward attractiveness. Societal norms dictate that hair is an essential part of a 
woman’s sexuality and gender identity, and any hair loss generates feelings of low 
self-esteem and anxiety from a perception of diminished attractiveness. Women are 
more likely than men to have a lowered quality of life (Cash et al 1993), and to restrict 
social contacts (Van Neste and Rushton 1997) as a result of hair loss. While men 
do consider androgenetic alopecia an unwanted and stressful event that diminishes 
their body image satisfaction (studies indicate 50% of men with mild hair loss and 
75% with moderate to severe hair loss report concern [Cash 1992] ), society tends to 
regard hair loss in men as expected and normal due to the greater visibility of hair 
loss within men.Clinical Interventions in Aging 2007:2(2) 190
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Current management options are limited, and even in 
positive responders, there is a signiﬁ  cant time delay before 
improvement becomes apparent. Regardless of which op-
tion is chosen, sufﬁ  cient time should be spent counseling 
the patient. While some women are content to be reassured 
that their hair loss is not a manifestation of a serious disease, 
many are sufﬁ  ciently concerned by the prospect of going bald 
to seek active treatment.
The two main pharmacological options are antiandrogens 
and minoxidil. Both treatments need to be continued indeﬁ  -
nitely to maintain a response. Nonpharmacological methods 
may also be appropriate in individual cases, such as chang-
ing hairstyles, camouﬂ  aging products, and hair replacement 
(Collins et al 2006). 
Epidemiology
While similarities exist between FPHL and androgenetic alo-
pecia in men, the susceptibility, age of onset, rate of progres-
sion, and pattern are different in the two sexes. Women are 
more conscious of subtle degrees of hair loss. Consequently, 
women often present with hair shedding prior to the develop-
ment of reduction in hair volume over the crown.
Despite this, the age of onset of FPHL is later than that 
seen in men. Twelve percent of women ﬁ  rst develop clinically 
detectable FPHL by age 29 years, 25% by age 49 years, 41% 
by 69 years, and over 50% have some element of FPHL by 
79 years. Only 43% of women aged 80 years and above show 
no evidence of FPHL (Gan and Sinclair 2005). 
While hair loss is common, severe hair loss as deﬁ  ned by 
Ludwig grade III (Ludwig 1977) or Sinclair grade 5 (Collins 
et al 2006; Yip and Sinclair 2006) (Figure 2) is uncommon 
and affects less than 1% of women. Severe bitemporal re-
cession as observed in male androgenetic alopecia is also 
uncommon in women in which the frontal hairline is usually 
preserved. 
Pathology and pathogenesis 
of FPHL
The histological hallmark common to male pattern hair 
loss (MPHL) and FPHL is miniaturization of hair fol-
licles with a progressive transformation of terminal hair 
follicles into vellus-like follicles. Terminal hair follicles 
have a shaft diameter of greater than 0.06 mm, whereas 
vellus-like follicles are defined as hairs with a hair shaft 
diameter of 0.03 mm or less and are thinner than the 
hair’s inner root sheath. In addition, women with FPHL 
have more follicles in the telogen or shedding phase of 
the hair cycle, and fewer in the anagen or growth phase 
(Headington 1984). 
The pathogenesis of MPHL involves activation of hair 
follicle cytoplasmic androgen receptors (AR) (Deplewski 
and Rosenﬁ  eld 2000). Both testosterone and dihydrotestos-
terone (DHT) activate the AR, however DHT binds 5 times 
more avidly than testosterone (Grino et al 1990) and DHT 
is thought to be the principle androgen involved in MPHL. 
Testosterone is converted into DHT by 5α-reductase (Bartsch 
et al 2000), and DHT in turn is converted into estrogen by 
the cytochrome P450 enzyme aromatase (Sawaya and Price 
1997). Two isoforms of 5α-reductase have been identiﬁ  ed 
and separated on pH optima, substrate afﬁ  nity, and tissue 
distribution (Jenkins et al 1992). The type 2 isoform is found 
in the dermal papilla of the hair follicle and inhibition of 
Grade I Grade II Grade III
Figure 1 Ludwig scale (1977).
Grade I: Perceptible thinning of the hair on the crown, limited in the front by a line situated 1–3 cm behind the frontal hair line.
Grade II: Pronounced rarefaction of the hair on the crown within the area seen in Grade I.
Grade III: Full baldness (total denudation) within the area seen in Grades I and II.Clinical Interventions in Aging 2007:2(2) 191
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this isoenzyme with ﬁ  nasteride is the principle treatment for 
MPHL (Kaufman et al 1998).
The histology of FPHL is indistinguishable for that seen 
in MPHL. While the role of androgens in the pathogenesis of 
MPHL has been clearly established, the role of androgens in 
FPHL is less clear. There are some women with FPHL who 
do not have elevated androgen levels and other androgen-
independent mechanisms are likely to be involved in the 
development of FPHL (Orme et al 1999). This may explain 
why post-menopausal women respond to ﬁ  nasteride less well 
than men. The pattern of hair loss seen in women is materially 
different to men. Bitemporal recession is less pronounced 
and vertex bald spots are almost never seen.
The lesser importance of androgen hormone activity in 
FPHL may be explained by the ﬁ  nding that, compared with 
men, women have lower circulating androgen levels, lower 
AR concentration in scalp skin, a lower concentration of 5α-
reductase enzymes and a concentration of aromatase, which 
functions to deactivate local androgens through conversion 
to estrogens (Sinclair and Dawber 2001). 
Clinical features, diagnosis, 
and natural history
Clinical features
The essential feature of FPHL is the pattern of the hair loss. 
Women develop diffuse thinning over the mid-frontal scalp 
with relative sparing of the anterior hair line. The thinning is 
most easily seen when the hair is parted in the midline, and 
the exposed scalp may resemble a Christmas tree. 
Hair loss may begin at any age after the onset of adrenarche 
and may precede pubarche and menarche. FPHL may present 
initially with either episodic or continuous hair shedding, prior 
to any noticeable reduction in hair volume. Alternatively some 
women present with diffuse thinning over the crown unaware 
of any increase in hair shedding (Sinclair and Dawber 2001). 
Examination of the scalp shows a widening of the central 
part with a diffuse reduction in hair density over the frontal 
scalp rather than baldness per se. Although these areas show 
the most marked reduction in hair density, there is usually some 
evidence of global reduction in hair density throughout the 
scalp. As a result, many women are not suitable for hair trans-
plantation due to poor donor hair population on the occipital 
scalp (Olsen 1994) Typically the frontal hairline is preserved 
although some women also develop bitemporal recession. 
Bitemporal recession is usually mild, starting postpubertally, 
and may run a course independent of mid-frontal hair loss. 
Traditionally, FPHL severity has been graded using the 
Ludwig scale mentioned above (Figure 1), which divides the 
severity of hair density reduction over the crown into three 
grades (Ludwig 1977). More recently, we developed a 5 
point visual analogue scale (the Sinclair Scale; Collins et al 
2006; Yip and Sinclair 2006) which assesses the degree of 
hair loss using the midline part (Figure 2). This is a simpli-
ﬁ  cation of the widely accepted Savin (1994) density scale 
(Figure 3), which classiﬁ  es FPHL into 8 stages of increasing 
crown balding, in addition to a special subcategory to detect 
frontal anterior recession.
Diagnosis
Increased hair shedding is common in the early stages of 
FPHL. When women present with increased hair shedding, 
but little or no reduction in hair volume over the mid-frontal 
scalp, various differential diagnoses should be considered, 
Figure 2 Sinclair Scale (Collins et al 2006; Yip and Sinclair 2006).
Grade 1: is normal. This pattern is found in all girls prior to puberty but in only forty-ﬁ  ve percent of women aged eighty or over.
Grade 2: shows a widening of the central part.
Grade 3: shows a widening of the central part and thinning of the hair on either side of the central part.
Grade 4: reveals the emergence of a diffuse hair loss over the top of the scalp.
Grade 5: indicates advanced hair loss.
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in particular acute and chronic telogen efﬂ  uvium. Acute 
telogen efﬂ  uvium is a self-limiting event, often triggered by 
physical illness, surgery, blood loss, or crash dieting. Chronic 
telogen efﬂ  uvium (CTE) can be secondary to thyroid disease, 
systemic lupus, drug ingestion (Table 1; Sinclair and Dawber 
2001) and iron deﬁ  ciency anemia. Iron deﬁ  ciency without 
anemia is not thought to cause hair shedding (Trost et al 
2006). CTE also occurs as a primary idiopathic event. Idio-
pathic CTE is characterized by excessive shedding of hair for 
at least 6 months without noticeable widening of the central 
parting. Other causes for diffuse hair shedding in women are 
included in Table 2 (Sinclair and Dawber 2001).
Scalp biopsy is the best way to distinguish between CTE 
and FPHL (Sinclair et al 2004). The importance in accurately 
distinguishing between these two entities lies in the differing 
natural histories, with CTE generally running a ﬂ  uctuating 
course but ultimately not leading to balding (Sinclair 2005), 
whereas FPHL without treatment invariably leads to a pro-
gressive reduction in hair volume over the frontal scalp. 
If a biopsy is required, the most information is gained from 
horizontal sectioning of the tissue and calculation of the termi-
nal to vellus hair ratio. A ratio of  <4:1 is considered diagnostic 
of FPHL while a ratio of  >8:1 is considered diagnostic of CTE. 
Ratios of 5:1, 6:1, and 7:1 are considered indeterminate. Mul-
tiple scalp biopsies reduce the risk of an indeterminate result 
or of underestimating FPHL. Underestimation of FPHL can 
occur with a single biopsy as FPHL is a diffuse process and 
the most common biopsy taken is 4 mm in diameter. 
I-4
I-1 I-2 I-3
III Advanced Frontal
II-1 II-2
Figure 3 Savin Scale (Savin 1994).
The Savin scale measures overall thinning of the crown scalp, and consists of 8 crown density images reﬂ  ecting a range from no hair loss to severe hair loss (Stages I-1, I-2, 
I-3, I-4, II-1, II-2, III, advanced). The ninth and ﬁ  nal image in the scale demonstrates frontal anterior recession.Clinical Interventions in Aging 2007:2(2) 193
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In one study where diagnostic accuracy using a single 
scalp biopsy was compared with 3 adjacent scalp biop-
sies, 21% of single biopsy specimens were indeterminate 
compared with 2% in the triple biopsy group (Sinclair et al 
2004). Given that the need for local anesthetic, the time to 
do the procedure, and the morbidity for the patient are not 
increased when three immediately adjacent scalp biopsies are 
performed, the authors recommend triple biopsy routinely.
While some authors have found a hyperandrogenic state 
underlying FPHL in up to 40% of women (Futterweit et al 
1988), fewer than 10% of our patients, who had been pri-
marily referred for assessment of their hair loss and found to 
have FPHL and hair follicle miniaturization on biopsy had 
evidence of virilization (Sinclair et al 2005). The presence 
of menstrual irregularity or marked acne or hirsutism in a 
woman presenting with FPHL should prompt the physician 
to investigate for an underlying cause, in particular, polycys-
tic ovary syndrome (PCOS). Rarely, virilizing tumors can 
cause hyperandrogenism with a recent onset of and rapidly 
progressive and severe hair loss from the scalp. 
Suitable screening investigations in women suspected of hy-
perandrogenism include serum estimation of androgens, prolac-
tin, FSH, LH, 17-hydroxyprogesterone, and estrogen as well as 
screening tests for fasting hyperglycemia and hyperlipidemia. 
Even when there is no clinical evidence of hyperandrogen-
ism, biochemical hyperandrogenism may be present. Futterweit 
and colleagues (1988) have found that around 25% of women 
with diffuse alopecia and biochemical hyperandrogenism may 
have no clinical androgen excess. The clinical relevance of these 
biochemical ﬁ  ndings is uncertain. Some case series and trials 
have suggested that efﬁ  cacy of antiandrogen medications at 
selected doses may be inﬂ  uenced by the biochemical androgen 
state of the patient (Burke et al 1985; Shum et al 2002; Thai et 
al 2002; Vexiau et al 2002; Trüeb 2004).
The clinical assessment of the woman with hair loss should 
incorporate a thorough history including a detailed drug history 
as well as a general examination for features of hyperandrogen-
ism. It is also useful to enquire whether the patient intends to 
become pregnant in the near future as antiandrogen drugs are 
potentially teratogenic. Not all patients need screening blood 
tests. It would seem reasonable to assess women for thyroid 
disease, iron deﬁ  ciency anemia, and consider endocrinological 
screening for women suspected of hyperandrogenism.
Natural history
Without treatment, FPHL is a progressive condition; however, 
the rate of its progression is highly variable. Hair shedding 
Table 1 Drug-induced alopecia (Sinclair and Dawber 2001)
Telogen efﬂ  uvium
Heparin
Warfarin
Propranalol/Metoprolol
Captopril/Enalopril
Allopurinol
Boric acid
Phenytoin
Glibenclamide
Amphetamines
Levadopa
Bromocryptine
Methysergide
Interferon
Albendazole/Mebendazole
Cimetidine
Colchicine (low dose)
Sulphasalazine
Penicillamine
Gold
Antithyroid action
Carbimazole
Propylthiouracil
Amiodorone
Lithium
Hypolipidemic agents
Cloﬁ  brate
Triparanol
Pro-androgen action
Oral contraceptive pill
Danazol
Testosterone
Anabolic Steroids
Note: Almost all chemotherapy agents can produce generalized hair 
shedding.
Table 2 Causes of alopecia in the female (Sinclair and Dawber 
2001)
Drug-induced hair loss (see Table 1)
Telogen efﬂ  uvium
Telogen gravidarum
Chronic telogen efﬂ  uvium
Early androgenetic alopecia
Diffuse alopecia areata
Scarring alopecia
Radiotherapy
Iron deﬁ  ciency
Starvation/Malabsorption/Crash diet
Hypothyroidism and hyperthyroidism
Chronic renal failure and hepatic failure
Syphilis
Acute lupus erythematosus
Advanced malignancyClinical Interventions in Aging 2007:2(2) 194
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is often episodic. Women commonly notice increased hair 
loss in the shower or in the brush each day for 2–3 months 
before the shedding returns to normal levels. 3–12 months 
may elapse before the shedding returns. The condition’s un-
predictability and relentless progression contributes greatly 
to the mental distress of affected women. 
Psychological morbidity
Hair loss in women produces greater psychological distress 
than in men. In a 1993 Glamour magazine survey, over half 
of the women stated “if my hair looks good, I look attractive 
no matter what I’m wearing or how I look otherwise,” and 
“if my hair isn’t right, nothing else can make me feel that I 
look good” (Etcoff 1999). A women’s hair is central to her 
femininity, beauty, and sexuality.
While hair loss can be distressing for males, a social ac-
ceptance and understanding of this phenomenon generally 
allows normal psychosocial functioning. In contrast, FPHL 
is not expected and less understood by society generating 
feelings of confusion and distress for the woman. A study 
has shown that 52% of women were very-to-extremely upset 
by their hair loss, compared with 28% of men (Cash 1992; 
Cash et al 1993). This distress results in lower self-esteem, a 
poor body image, feelings of guilt, problems with sleep and 
day-to-day function, and restriction of social activities. 
After the initial shock of diagnosis, most women adopt a 
variety of coping mechanisms (Cash 2001). “Compensation” 
refers to efforts to offset the hair loss with other physical 
improvements such as greater attention to dress in order to 
create positive body images. “Concealment” of hair loss aims 
to avoid associated negative body-image feelings. Women 
may want to avoid the negative reactions from family, 
friends, and even strangers, and may wear hats or wigs to 
achieve this. Thirdly, compulsive activities of reassurance 
designed to minimize negative body-image feelings such 
as excessive checking or ﬁ  xing of one’s hair in front of the 
mirror may occur. 
Clearly, the psychological distress resulting from FPHL 
is an integral part of disease entity and needs to be addressed 
in any management regime. 
Management
Treatment options
Pharmacological
Pharmacological options can be divided into drugs with 
androgen-independent and androgen-dependent mechanisms 
of action.
Androgen-independent medications
Minoxidil
Currently the only androgen-independent medication in 
widespread use is minoxidil topical solution. This medi-
cation’s proposed mechanism of action is by affecting hair 
cycling, causing premature termination of telogen, and prob-
ably prolonging anagen (Messenger and Rundegren 2004). 
Understanding exactly how minoxidil exerts these effects 
is currently the subject of intense research. Although this 
is available in both 2% and 5% preparations, only the 2% 
solution is currently FDA-approved for FPHL (DeVillez et al 
1994). A study comparing the efﬁ  cacy of the two concentra-
tions using target area hair counts at 48 weeks as a primary 
endpoint showed a mild nonsigniﬁ  cant advantage for the 5% 
solution (Olsen et al 2002). 
Usually 1 ml of minoxidil is applied twice daily to dry 
scalp with a dropper. This is left for 1 hour before shampoo-
ing or wetting of the hair is allowed to maximize medication 
absorption. Patients should be warned that in the initial 2–8 
weeks, a temporary telogen efﬂ  uvium may occur, which is 
self-limiting and subsides when subsequent anagen regrowth 
begins, and should not be a cause for treatment cessation. 
Common adverse effects of minoxidil include scalp irritation 
including dryness, scaling, itching, and/or redness (Friedman 
et al 2002). Speciﬁ  c to its use in FPHL, hypertrichosis may 
occur, primarily on the cheeks and forehead. If this occurs, it 
generally disappears within 4 months of ceasing the medica-
tion. Treatment should be continued for at least 12 months 
before an accurate appraisal of efﬁ  cacy can be made.
Recently, it has been found that most cases (82%) of 
scalp irritation after use of topical minoxidil results from a 
contact dermatitis to propylene glycol, one of the vehicles 
of the solution, rather than the minoxidil itself (Leffek 
and Herrick 2006). There is emerging data on a new foam 
vehicle for minoxidil which has signiﬁ  cantly reduced levels 
of propylene glycol indicating at least equivalent efﬁ  cacy 
and increased preference by subjects due to the lack of the 
sticky residue associated with current formulations (Lucky 
et al 2004).
Androgen-dependent medications
The use of all androgen-dependent medications to treat FPHL 
carries a risk of causing abnormalities in the genitalia of the 
male fetus. Thus, these medications are contraindicated in 
women who are pregnant, which leads many physicians to 
recommend that women start and remain on an oral contra-
ceptive pill throughout their course of treatment with these Clinical Interventions in Aging 2007:2(2) 195
Female pattern hair loss
medications. As with minoxidil, all androgen-dependent 
medications need to be continued for at least 1 year before 
an accurate appraisal of efﬁ  cacy can be made. 
Finasteride
Finasteride works by inhibiting 5α-reductase II enzyme, which 
is responsible for catalyzing the conversion of testosterone 
to the much more active chemical 5 DHT. Thus, ﬁ  nasteride 
suppresses overall androgen activity by restricting total cir-
culating androgen activity. Large scale studies on its efﬁ  cacy 
are currently limited, with one large multicenter randomized 
placebo-controlled trial failing to ﬁ  nd any change in hair 
growth or progression of hair loss with ﬁ  nasteride 1 mg/day 
in postmenopausal women with FPHL over a 1 year follow-up 
period (Price et al 2000). However, smaller case reports and 
case series have demonstrated efﬁ  cacy for ﬁ  nasteride 1.25 
mg/day in 4 cases of FPHL in both pre- and post-menopausal 
women with hyperandrogenism (Shum et al 2002), ﬁ  nasteride 
2.5 mg/day in 5 cases of FPHL in post-menopausal women 
without hyperandrogenism (Trüeb 2004), and ﬁ  nasteride 5 mg/
day in 1 case of FPHL in a post-menopausal woman without 
hyperandrogenism (Thai et al 2002). Finasteride does appear 
to be successful in some patients, but further large scale studies 
are required to determine optimal dosing regimes. 
Finasteride is generally well tolerated. Infrequent side 
effects in female patients include breast tenderness and 
increased libido, which are most common in the ﬁ  rst year of 
therapy, reversible on dose reduction, and tend to diminish 
over time with continued use. 
Cyproterone acetate
This medication inhibits gonadotropin-releasing hormone 
(GnRH) and blocks androgen receptors. Other uses include 
prostate cancer, hirsutism, and severe acne. In Australia, it 
is commonly used combined with estradiol as an oral con-
traceptive pill named Diane-35. 
A number of studies suggest a role for cyproterone 
acetate, with some suggesting that this role is greater in 
patients with evidence of hyperandrogenism. One moderately 
large study of 25 subjects aged between 31 and 35 years 
with FPHL showed that Diane-35 used for 6–9 months 
clearly decreased the loss of hair, hair thinning, and sebor-
rhea Brzezinska-Weislo 2003). Another study compared 8 
control patients with FPHL receiving placebo treatment with 
20 patients with FPHL treated with 50 μg ethinyloestradiol 
plus 2 mg cyproterone acetate daily with additional 20 mg 
cyproterone acetate on days 5–20 of the menstrual cycle. 
The authors found that patients receiving active treatment 
enjoyed reduced hair shedding without actual increased hair 
regrowth (Lucky et al 2004). The best study investigating 
cyproterone actetate was a 12-month randomized trial to 
compare the use of topical minoxidil 2% and cyproterone 
acetate in 66 women with FPHL. These authors found that 
minoxidil 2% was more effective in women without evidence 
of hyperandrogenism, whereas cyproterone acetate was more 
effective in those with signs of hyperandrogenism (Vexiau 
et al 2002). Comparison of two antiandrogen medications (ie, 
spironolactone and cyproterone acetate) was undertaken in 
another study involving 80 women with biopsy conﬁ  rmed 
FPHL. The authors found that overall, 88% of women either 
experienced improvement or had no progression of their 
hair loss with no signiﬁ  cant difference in efﬁ  cacy between 
individual medications (Futterweit et al 1988). 
In contrast, there is only one signiﬁ  cant randomized 
study which has shown no beneﬁ  t for cyproterone acetate. 
This study compared ﬂ  utamide, ﬁ  nasteride, and cyproterone 
acetate in 36 hyperandrogenic women and failed to show a 
signiﬁ  cant response for cyproterone acetate (as well as ﬁ  n-
asteride) (Carmina and Lobo 2003). It would appear that the 
balance of evidence supports a role for cyproterone acetate 
in FPHL. Further research would need to be done to clarify 
whether this medication has a greater role in those patients 
with evidence of hyperandrogenism.
Treatment doses utilized vary but it appears the most 
effective is 100 mg/day on days 5–15 of the menstrual 
cycle supplemented by 50 μg ethinyl estradiol on days 5–25 
(Dawber et al 1982). The side effect proﬁ  le includes men-
strual disturbances, weight gain, loss of libido, depression, 
breast tenderness, and gastrointestinal upsets. 
Spironolactone
Spironolactone is used widely to treat FPHL and hirsutism. 
It acts as an androgen antagonist by competitively blocking 
androgen receptors, as well as inhibiting ovarian androgen 
production (Shaw 1996). In the USA it is the most widely 
used antiandrogen to treat FPHL. The usual daily dose is 
100–200 mg. Published studies supporting efﬁ  cacy are 
limited but as mentioned above, a recent open intervention 
study concluded that spironolactone 200 mg/day was equally 
effective in either restoring hair growth or preventing further 
progression of hair loss compared with cyproterone acetate 
at a dose of either 50 mg/day or 100 mg/day given for 10 
days every menstrual cycle (Sinclair et al 2005).
The side effect proﬁ  le of spironolactone is perhaps more 
varied compared with other medications, due partly to its Clinical Interventions in Aging 2007:2(2) 196
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additional actions as an aldosterone antagonist. These include 
postural hypotension, electrolyte disturbances, menstrual 
irregularities, fatigue, urticaria, breast tenderness, and hema-
tological disturbances. Because of these known side effects, it 
is recommended that women have regular blood pressure and 
electrolyte monitoring, especially in the ﬁ  rst few months of 
treatment. Further caution with its use needs to be exercised 
in the patient with renal abnormalities since it can potentially 
cause serious electrolyte disturbances. 
Flutamide
Flutamide is a potent antiandrogen, acting via androgen 
receptor antagonism. As such, it is commonly used to treat 
advanced prostate cancer and hirsutism. Being one of the 
newer antiandrogens, there is limited medical literature on its 
use in FPHL. One randomized study suggested that ﬂ  utamide 
at a dose of 250 mg/day could lead to greater improvements 
in stemming hair loss after 1 year of treatment compared 
with ﬁ  nasteride and cyproterone acetate (Carmin and Lobo 
2003). Another randomized controlled trial found a signiﬁ  -
cant treatment advantage for ﬂ  utamide over spironolactone 
in the treatment of hirsutism, the reduction of total acne and 
seborrhea, and the slowing or halting of hair loss (Sinclair 
et al 2005).
Adverse effects due to ﬂ  utamide are potentially severe. 
These include hepatic dysfunction and breast tenderness, 
both of which are dose-related. The rate of hepatotoxicity has 
been estimated at 3 in 10,000 users (Sinclair et al 2005). It is 
recommended that serial liver transaminases are monitored 
in the ﬁ  rst few months of treatment, and that ﬂ  utamide be 
stopped or not commenced if transaminase levels exceed 
twice the normal limits.
Cosmetic aids (Collins et al 2006)
Since so much of the morbidity of FPHL lies in body image 
disturbances, cosmetic aids are an integral part of management 
options. These incorporate hair styling techniques, camouﬂ  age 
products, hair replacements, hair accessories, and additions.
Hairstyling
Different hairstyling options can be canvassed by a woman’s 
individual hair stylist, and it may take 3 or 4 different haircuts 
before a woman ﬁ  nds her optimal look. Some useful tips 
applicable in the woman with FPHL include: getting greater 
hair volume and lift from shorter styles; disguising central 
thinness by a side or zigzagging part; adding soft layers at the 
top to allow pulled back hair to have more style; taking some 
weight off the top; using wide-toothed combs or brushes to 
allow thin hair to ﬂ  ow through without breakage; using a 
friction-free towel that blots hair and absorbs most of the 
moisture rather than damaging thin hair with towel drying; 
coloring hair to make hair look thicker and appear to give 
it more volume; styling with a body wave with soft or tight 
curls to give hair more bounce and fullness; and using hair 
sprays and foams that are light and nondrying to give volume 
and prevent breakage.
Camouﬂ  aging products
Camouﬂ  aging products cover exposed areas on the scalp and 
hide visible hair loss. They also provide lift at the base of the 
hair shaft, which adds volume. These products are best suited 
to those women with mild to moderate hair loss, whereas 
those with more severe hair loss may not achieve a natural 
appearance after application. Most camouﬂ  aging products 
do not rub off easily, and are resistant to stresses such as 
perspiration, exercising, and swimming. Removal can be 
achieved simply by shampooing. In addition, camouﬂ  aging 
products are compatible with topical minoxidil. 
The most commonly used products include hair build-
ing ﬁ  bers, scalp spray thickeners, alopecia masking lotion, 
and topical shading. Hair building ﬁ  bers are keratin ﬁ  bers 
available in a range of natural hair colors. They come in a jar 
with a pepper-shaker type top. A gentle shake of this jar onto 
the thinning areas of the scalp creates density throughout the 
area, reducing the appearance of thinning hair, which begins 
to work in about 30 seconds. Scalp spray thickeners cover 
thinning areas by bonding ﬁ  bers to hair to create density and 
add color. Although effective, they can be messy to use, so 
care needs to be exercised to minimize staining of clothes 
and ﬁ  ngers. Alopecia masking lotion is a tinted lotion that is 
dabbed onto thinning areas of the scalp to create the 1 of fuller 
hair. It is manufactured in a tube with a special applicator. 
One advantage is that it is not sticky or greasy thus will not 
stain clothing. One tube usually lasts 3–4 months. Topical 
shading is a tinted pressed powder that is used to cover the 
scalp in thinning areas and coat hair strands to create a fuller 
look. Application involves dabbing the powder onto the scalp 
by using a sponge-tipped applicator.
Different types of scalp skin respond differentially to 
different types of camouﬂ  aging. In general, for oily to nor-
mal skin on the scalp, use of a pressed powder allows good 
absorption and prevents a shiny scalp. For dry scalp skin, 
a cream prevents further dryness. Because ﬁ  bers need hair 
to bind to, individuals with advanced hair loss generally do 
better with sprays and creams.Clinical Interventions in Aging 2007:2(2) 197
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Hair replacement
In addition to measures described above, hair extensions can 
be useful for women with mild hair loss who simply desire 
more length and volume. These can be clipped on daily or 
attached permanently. However, potential damage may occur 
if they are applied to hair that breaks easily, so selection of 
appropriate hair is paramount.
For those women with moderate to severe hair loss, hair-
styling and camouﬂ  aging is often not enough. An integration, 
hairpiece, or wig may be better options.
An integration is made of fabric or skin-like material 
with replacement hair attached to it and gaps through which 
native hair can be pulled through. By blending integrations 
with natural hair from thinning areas, increased volume of 
hair is created, which creates the appearance of a full head of 
hair. However, if it is worn for extended periods, it can cause 
scalp irritation, as well as stress to existing hair, resulting in 
damage and hair breakage.
For more extensive hair loss that is too fragile to withstand 
integrations, hairpieces or wigs may be used. Hairpieces con-
tain skin-like breathable material and hold the attached hair 
securely in position. They are attached to the scalp by either 
adhesive tape or alternatively hair clips for ease of removal 
at the end of the day. They can be matched to existing scalp 
tone, hair texture, and color providing as natural a look as 
possible. They are robust and can be worn 24 hours a day.
Wigs are for the advanced stages of hair loss. A good 
quality, well-ﬁ  tted wig allows unrestricted daily activities, 
including working out at the gym, swimming, or going out on 
a windy day. Current manufacturing offers a wide variety of 
sizes, styles, texture and colors, the choice of being custom-
made or machine-made, being made of synthetic or human 
ﬁ  bers, and containing a polyester, polyurethane, nylon, or 
silicone-derived wig base, all of which provide subtle differ-
ences tailored to the personal preferences of the individual.
Hair accessories and additions
Fashion accessories can satisfactorily conceal localized or 
diffuse patches of hair loss and include hats, scarves, ban-
danas, and turbans. Hair additions and accessories include 
combs and headbands with hair attached to them, ponytails 
that easily attach to existing hair, and hair scrunchies.
Surgical treatments
Hair transplantation
Ideal surgical candidates for hair transplantation are those 
women with high hair-density in the donor site over the 
occipital scalp and extensive hair loss or thinning of the 
frontal scalp (Olsen et al 2005). Patients should be encour-
aged to develop realistic expectations of the potential results 
achievable. Technical details of transplantation are beyond 
the scope of this paper, however, in brief, the procedure 
is done under local anesthetic whereby 1 session would 
involve the transplantation of 800–1200 grafts. In most 
women, 1–3 sessions are undertaken depending on the 
degree of hair loss and the availability of donor sites (Unger 
and Unger 2003). Each session is undertaken approximately 
6 months apart since results can take up to 6 months after 
a procedure to become evident. Local complications of the 
procedure include facial edema, scalp erythema, crusting, 
post-operative bleeding, infection, swelling, temporary 
headaches, temporary numbing of the scalp, and abnormal 
scarring of the graft (Unger and Unger 2003). Occasionally 
with densely packed grafts, temporary telogen efﬂ  uvium 
may occur for a few weeks after the procedure. There is 
some evidence that this can be reliably prevented by the use 
of a topical minoxidil solution applied twice daily to the 
recipient and potential donor areas for 1 week before and 
5 weeks after operation (Avram et al 2002; Uremia et al 
2002). Often the option of hair transplantation in FPHL is 
overlooked, and is not favored as much as in male andro-
genetic alopecia, but expert opinion suggests that many 
women can expect results that are at least as good as those 
seen in transplanting for early male androgenetic alopecia 
(Unger and Unger 2003).
Scalp reduction
This option is less popular compared with hair transplanta-
tion. It involves bringing hair-bearing skin closer together by 
removing the central scalp affected by the alopecia. Some-
times it is performed in conjunction with hair transplantation 
to optimize cosmetic outcomes. Disadvantages of this pro-
cedure increase with time and include diminishing efﬁ  cacy 
due to the unpredictability of subsequent individual hair loss, 
increasing cosmetic visibility of excision scars, potential 
gradual widening of scars due to stretching of adjacent scalp 
skin, and the usual need for more than one scalp reduction to 
effectively address hair loss (Unger and Unger 2003).
Experimental
Dutasteride
Dutasteride is a more potent 5α-reductase inhibitor 
than finasteride, working by inhibiting both type I and 
type II 5α-reductase. Whereas type II 5α-reductase Clinical Interventions in Aging 2007:2(2) 198
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concentrations are much higher than those of type I 5α-
reductase, the additional inhibitory effect on androgen 
activity produced by dutasteride may translate into greater 
clinical efficacy. It is commonly used to treat benign 
prostatic hypertrophy but is not approved by the US FDA 
for the treatment of either male or female androgenetic 
alopecia. Significant issues with teratogenicity arise from 
the long biological half life (months), and this drug is best 
avoided in women who may become pregnant.
Phase 1 and 2 trials conducted exclusively in men 
demonstrated that at a dose of 2.5–5.0 mg/day, dutasteride 
suppresses almost 100% of serum DHT activity, whereas 
ﬁ  nasteride at a dose of 5 mg/day suppresses only 70% of 
DHT. Phase 2 preclinical trials showed that after 6 months 
of treatment, there was a 30% increased improvement in hair 
count when comparing 0.5 mg of dutasteride with 5 mg of 
ﬁ  nasteride (GSK 2006). 
Future agents
Current gene discovery research may identify a number of 
novel genes that regulate hair growth, hair cycling, and the 
hormone-induced changes seen at puberty in the near future. 
This research may lead to topically delivered therapy, tar-
geting critical pathways to stimulate hair growth. If these 
agents can be incorporated into hair follicle cells, permanent 
alteration of hair growth, and resultant reliable re-growth of 
hair may be achieved. 
Monitoring clinical response
Monitoring clinical response is an often under-emphasized 
aspect of management of FPHL. Its importance is underlined 
by the extended durations of treatment required to achieve 
often very subtle treatment responses. One practical way 
of monitoring response is by encouraging periodical scalp 
photographs preferably by a trained medical photographer 
before treatment and every 6 months thereafter thus allowing 
subtle improvements to be easily observed. Less reliable, but 
logistically easier methods include self-counting the number 
of hairs lost each day; however, accuracy of this method 
may be limited by ﬂ  uctuations in hair loss amongst different 
seasons, weeks, and even days (Sinclair et al 2000). Another 
way is to temporarily suspend drug treatment after 12 months 
use and observe for an increased amount of hair shedding 
4–6 weeks later, indicating successful treatment. Aside from 
giving evidence of tangible results to both patient and physi-
cian, feedback of positive treatment results improves ongoing 
compliance of the patient with treatment. 
Conclusion
FPHL is an under-recognized entity. Signiﬁ  cant hair loss is 
seen in over ¼ of females over the age of 50. Satisfactory 
management of this condition requires a knowledge of 
possible underlying causes, physical comorbidities, possible 
differential diagnoses, and the various therapeutic modalities 
available. It also requires an appreciation of the potential 
psychological effect of hair loss on affected individuals, and 
sensitivity during patient consultations.
The condition is progressive without treatment. Current 
pharmacological treatment stems further progression and can 
also stimulate partial regrowth.
Regardless of which medication is utilized, response is 
slow, and requires patience and persistence in both patient and 
clinician. The cosmetic effects of this condition should not be 
underestimated, thus cosmetic aids and surgical options are 
both important adjunctive options that need to be discussed 
with these patients in addition to pharmacotherapy.
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